NICE: faster access to modern treatments? Analysis of guidance on health technologiesBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7324.1300 (Published 01 December 2001) Cite this as: BMJ 2001;323:1300
All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
We found Raftery's discussion of the workings of NICE most helpful,
but think that the issue of affordability needs further discussion.
Raftery states that the 22 judgements he reviewed would cost the NHS an
additional £200 million i.e. 0.5% of annual NHS spend in England and Wales
and that this should be readily met within the 9% annual cash increase the
NHS received this year.
But once increased pay and prices and a host of other cost pressures
are taken into consideration, the real (ie volume) growth in NHS spending
this year is only about 2% (and not, as stated by Government, around 6%).
Paying for NICE guidance would therefore account for 25% of available
growth monies, and given other "must dos" (such as National Service
Frameworks and waiting times targets), NICE costs are a major cost
pressure for Health Authorities and Primary Care Trusts.
The Department of Health say that the cost of NICE guidance has
already been built in to the NHS budget this year. But what about next
year? With statutory obligations on health authorities and Primary Care
Trusts to fund NICE recommendations imminent, how much is to be earmarked
next year? And if the sums are not enough, what is the NHS expected to
stop doing in order to meet its growing list of 'must dos'?
Shahed Ahmad, Senior Registrar in Public Health Medicine
John Appleby, Director, Health Systems Programme
King's Fund, London W1M 0AN
Competing interests: No competing interests